Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment
60 Patients to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA to …